Apogee Therapeutics, Inc. Stock
Stocks
APGE
US03770N1019
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
06:00:00 03/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 135.07 USD | -0.01% |
|
+0.07% | +78.95% |
| 03/09 | AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics | MT |
| 03/09 | Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from S&P Biotechnology Select Industry Index | CI |
| Market Cap | 10.19B 8.77B 8.25B 7.53B 14.09B 962B 14.13B 97.45B 37.82B 493B 38.25B 37.42B 1,590B | P/E 2026 * |
-27.8x | P/E 2027 * | -21.7x |
|---|---|---|---|---|---|
| Enterprise Value | 9.22B 7.94B 7.47B 6.82B 12.76B 871B 12.8B 88.25B 34.25B 447B 34.64B 33.88B 1,440B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 1,135x |
| Free-Float |
95.17% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| APGE | Delayed | |
CBOE
| APGE | Real-time |
Last Transcript : Apogee Therapeutics, Inc.
| 1 day | -0.01% | ||
| 1 week | +0.07% | ||
| Current month | -0.01% | ||
| 1 month | +0.66% | ||
| 3 months | +48.59% | ||
| 6 months | +86.79% | ||
| Current year | +78.95% |
| 1 week | 134.99 |  | 135.09 |
| 1 month | 134.25 | | 135.09 |
| Current year | 60.35 | | 135.09 |
| 1 year | 35.39 | | 135.09 |
| 3 years | 14.19 | | 135.09 |
| 5 years | 14.19 | | 135.09 |
| 10 years | 14.19 | | 135.09 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 36 | 01/09/2022 | |
Jane Henderson
DFI | Director of Finance/CFO | 60 | 01/01/2023 |
Tim Piringer
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Fox
BRD | Director/Board Member | 54 | 22/06/2023 |
William Jones
BRD | Director/Board Member | 62 | 01/06/2023 |
| Director/Board Member | 36 | 01/06/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/9/26 | Fairmount Funds Management LLC
| Issuer sale | Company | -340,855 | 0.6087% | |
| 3/9/26 | Issuer sale | Director | -48,780 | 0.0871% | ||
| 3/9/26 | Venrock Associates
| Issuer sale | Company | -2,115,853 | 3.7784% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.01% | +0.07% | +263.78% | +446.62% | 10.19B | |
| -2.54% | -2.84% | -1.90% | +14.52% | 48.93B | |
| -0.40% | +1.03% | +439.20% | +499.20% | 45.01B | |
| -1.42% | +2.30% | +45.46% | +19.36% | 44.07B | |
| -1.22% | -2.31% | +12.40% | +71.48% | 40.73B | |
| +0.53% | -1.36% | +16.04% | +48.23% | 33.52B | |
| -0.21% | +9.14% | - | - | 17.77B | |
| -0.35% | -1.56% | +22.59% | +116.19% | 16.5B | |
| -1.01% | +0.50% | +15.83% | +27.98% | 14.67B | |
| -1.65% | -1.03% | +77.75% | +37.63% | 13.77B | |
| Average | -0.83% | +0.49% | +99.02% | +142.36% | 28.52B | |
| Weighted average by Cap. | -1.00% | +0.11% | +101.29% | +134.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 8.33M 7.17M 6.75M 6.16M 11.53M 787M 11.56M 79.72M 30.94M 404M 31.29M 30.61M 1.3B |
| Net income | -350M -301M -283M -259M -484M -33.05B -486M -3.35B -1.3B -16.95B -1.31B -1.29B -54.62B | -471M -405M -381M -348M -651M -44.42B -653M -4.5B -1.75B -22.79B -1.77B -1.73B -73.43B |
| Net Debt | -962M -827M -778M -711M -1.33B -90.78B -1.33B -9.2B -3.57B -46.58B -3.61B -3.53B -150B | -731M -629M -592M -541M -1.01B -69.04B -1.01B -7B -2.71B -35.42B -2.75B -2.69B -114B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/09/26 | USD 135.07 | -0.01% | 5,142,068 |
| 01/09/26 | USD 135.08 | 0.00% | 1,090,742 |
| 31/08/26 | USD 135.08 | +0.08% | 1,811,685 |
| 28/08/26 | USD 134.97 | +0.01% | 733,857 |
| 27/08/26 | USD 134.96 | +0.01% | 1,137,230 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- APGE Stock
Select your edition
All financial news and data tailored to specific country editions
